why choose us

First received: October 10, 2022

Clinical Trial: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Double-Expressor Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Brief Summary: This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma.Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine.It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill…

Read more